DUBLIN–(BUSINESS WIRE)–The “Bispecific Antibodies Market Industry Trends and Global Forecasts to 2035: By Therapeutic Area, Mechanism of Action, Target Antigen, Antibody Format, Key Geographical Regions and Key Players” report has been added to ResearchAndMarkets.com’s offering.
The global bispecific antibodies market is estimated to grow from USD 8.93 billion in 2025, to USD 16.81 billion by 2035, at a CAGR of 6.5% during the forecast period to 2035.
Bispecific Antibodies Market: Growth and Trends
Assessing the therapeutic capabilities of monoclonal antibodies and their effective application in treating numerous diseases has transformed the pharmaceutical sector. Currently, extensive studies are underway to develop engineered antibody therapeutics to enhance treatment outcomes. Several decades ago, bispecific antibodies were developed by adding additional antigen binding sites to monoclonal antibodies.
The primary goal of these bivalent molecules has been to guide cytotoxic immune effector cells to enhance the destruction of tumor cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and various other cytotoxic processes driven by the immune effector cells. This modified version of antibody-based treatments is presently attracting significant interest from pharmaceutical firms. In recent years, clinical trials have shown significant advantages provided by innovative bispecific antibody treatments for various target conditions, creating substantial opportunities for those involved in developing these therapies.
The bispecific antibodies market is driven by major factors including the growing cancer burden, along with an increasing focus on personalized medicine for blood cancers, autoimmune diseases, and other such disorders. The rising financial burden of chronic diseases, along with its impact on death rates, has resulted in a heightened need for efficient bispecific antibody therapies that can address various oncological and non-oncological conditions.
Consequently, R&D initiatives from both industry and non-industry entities, along with the increasing need for efficient bispecific antibody treatments, are expected to drive the bispecific antibodies market in the coming decade.
Bispecific Antibodies Market: Key Segments
Hematological Malignancies is the Fastest Growing Segment of Bispecific Antibodies Market
At present, genetic disorders hold the maximum share of the bispecific antibodies market. It is worth highlighting that the bispecific antibodies market for hematological malignancies is likely to grow at a relatively higher CAGR.
Bispecific Antibodies Acting Through T-Cell Retargeting / Activation Occupy the Largest Share During the Forecast Period
Currently, T-cell retargeting / activation holds the maximum share of the bispecific antibodies market. However, bispecific antibodies acting through cytokines retargeting / neutralization are anticipated to capture the highest market in the near future.
Bispecific Antibodies Targeting CD3 x BCMA is the Fastest Growing Segment of the Market
At present, therapies targeting factor IXa x factor X holds the maximum share of the bispecific antibodies market. It is worth highlighting that the drugs intended to target CD3 x BCMA are likely to grow at a relatively higher CAGR.
Asymmetric Bispecific Antibodies are Likely to Dominate the Market During the Forecast Period
Currently, asymmetric antibodies hold the maximum share of the bispecific antibodies market. This trend is unlikely to change in the foreseeable future.
North America Accounts for the Largest Share of the Market
We anticipate North America to capture the majority of the bispecific antibodies market. Further, it is worth highlighting that Europe is expected to grow at a higher CAGR over the coming years.
Bispecific Antibodies Market: Key Insights
- The landscape of bispecific antibody therapeutics has steadily evolved in the past decade; over 400 clinical / preclinical candidates are being evaluated by over 120 drug developers worldwide.
- The current pipeline features a number of clinical stage bispecific antibody drug candidates, capable of targeting a range of biological antigens in order to potentially treat multiple target indications.
- In fact, industry stakeholders are engaged in the development of over 85 bispecific antibody technology platforms, aiming to mitigate the existing manufacturing challenges associated with such therapies.
- The growing interest is evident from the rise in partnership activity; companies are actively entering into strategic agreements in order to expand their bispecific antibody portfolio.
- Since 2010, nearly 280 clinical trials have been registered to evaluate the safety and efficacy of various bispecific antibody therapeutics; majority of these studies are being conducted across sites in the US.
- In order to efficiently promote these therapies, drug developers are actively exploring diverse promotional strategies with an aim to sustain their position in the market.
- With the growing focus on development pipeline and encouraging clinical results, the market is expected to witness an annualized growth rate of over 6.5%, during the next decade.
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Bispecific Antibodies Market: Research Coverage
- Market Sizing and Opportunity Analysis
- Market Landscape
- Key Insights
- Technology Assessment Framework
- Big Pharma Analysis
- Company Profiles
- Partnerships and Collaborations:
- Contract Services for Bispecific Antibody Therapeutics
- Clinical Trial Analysis
- Case Studies
- SWOT Analysis
Key Players in the Bispecific Antibodies Market Profiled in the Report Include
- Akeso Biopharma
- Alexion
- Amgen
- Genmab
- Immunocore
- Janssen Research & Development
- Linton Pharm
- Merck
- OncXerna Therapeutics
- Pfizer
- Roche
- Taisho Pharmaceutical
- Zymeworks
Report Scope
Therapeutic Area
- Autoimmune Disorders
- Genetic Disorders
- Hematological Malignancies
- Ophthalmic Disorders
- Skin Cancers
- Solid Tumors
Mechanism of Action
- Cytokines Retargeting / Neutralization
- Dual Ligands Blocking
- Resistance Factors Co-targeting
- Targeting Tumor Angiogenesis
- T-Cell Retargeting / Activation
- Others
Target Antigen
- C5-Albumin
- CD20 x CD3
- CD3 x BCMA
- CD3 x CD19
- EGFR x cMET
- EpCAM x CD3
- Factor IXa x Factor X
- gp100 x CD3
- HER2 x HER2
- PD-1 x CTLA-4
- PD-L1 x TGFa
- TNF-a x HSA
- VEGF x DLL4
- VEGF-A x ANG2
Antibody Format
- Asymmetric
- Fragments
Geography
- North America (US, Canada, Rest of North America)
- Europe (Germany, France, Italy, Spain, UK, Rest of Europe)
- Asia (India, China, Japan, South Korea, Rest of Asia)
- Rest of the World
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
For more information about this report visit https://www.researchandmarkets.com/r/tzy270
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900